Oregon Health & Science University (OHSU Health) Dermatology

Topics

• Dermatology and Skin Diseases 593
• Cutaneous Melanoma Detection and Management 268
• Chronic Myeloid Leukemia Treatments 232
• Contact Dermatitis and Allergies 156
• Autoimmune and Inflammatory Disorders 146
• Cutaneous lymphoproliferative disorders research 111
• Psoriasis: Treatment and Pathogenesis 98
• Asthma and respiratory diseases 90
• Cancer Immunotherapy and Biomarkers 75
• Autoimmune Bullous Skin Diseases 74
• Nail Diseases and Treatments 73
• Skin Protection and Aging 73

Most cited

1. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.

   Journal of the American Academy of Dermatology · 2024 · 210 citations · Kathryn Schwarzenberger

2. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).

   The British journal of dermatology · 2021 · 502 citations · Eric Simpson

3. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.

   The New England journal of medicine · 2023 · 275 citations · Eric Simpson

4. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.

   Lancet (London, England) · 2021 · 463 citations · Eric Simpson

5. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.

   JAMA dermatology · 2021 · 414 citations · Eric Simpson

6. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.